BioXcel Therapeutics Inc Corporate Analyst Meeting Transcript
Okay. Well, good morning, everyone, and thank you all for joining us today to discuss the potential of our lead neuroscience program, BXCL501, which is our proprietary sublingual thin-film formulation of dexmedetomidine.
So just for -- this is the last time I'm going to say dexmedetomidine. I'm doing it for a certain person in this room. I know he knows it. So we'll call it Dex from this point on, okay? So dexmedetomidine, Dex. We'll call it Dex, okay, which is being developed for acute treatment of agitation across neuropsychiatric diseases. Today, we look forward to discussing the global clinical development plans, the market opportunity, preliminary data results from our Phase I study, commercialization strategy as well as our indication expansion plans for BXCL501.
With us today is an outstanding panel of key opinion leaders that will contribute to the acute agitation overview with respect to each of the proposed neuropsychiatric indications. But for now, let me turn the podium over to our Chief Executive Officer,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |